Literature DB >> 6530890

Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?

D P Mertz, R Eichhorn.   

Abstract

Twenty male hyperuricaemic patients with normal kidney function were studied and it was found that the serum concentrations and excretions rates in the 24-hour urine of allopurinol and oxipurinol do not differ significantly after 9 days of oral treatment with either 300 mg allopurinol or a combination of 300 mg allopurinol and 60 mg benzbromarone daily. The sum of the excretion rates of the two pyrazolopyrimidines in the 24-hour urine represents 80.9% and 77.1%, respectively of the daily dose of allopurinol given alone or in combination with benzbromarone. As expected, the hypouricaemic effect of the combined therapy turned out to be stronger than that observed after monotherapy with allopurinol, due to the uricosuric component of benzbromarone. The difference was found to be highly significant.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6530890     DOI: 10.1007/bf01712184

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  8 in total

1.  [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].

Authors:  F Matzkies; G Berg
Journal:  Dtsch Med Wochenschr       Date:  1976-10-22       Impact factor: 0.628

2.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

3.  [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].

Authors:  D P Mertz; K Borner
Journal:  Med Welt       Date:  1983-09-09

4.  High-performance liquid chromatographic assay for allopurinol and oxipurinol in human plasma.

Authors:  W G Kramer; S Feldman
Journal:  J Chromatogr       Date:  1979-01-01

5.  [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].

Authors:  D P Mertz
Journal:  Dtsch Med Wochenschr       Date:  1976-08-27       Impact factor: 0.628

6.  [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].

Authors:  H R Arntz; H R Dreykluft; H Leonhardt
Journal:  Fortschr Med       Date:  1979-07-19

7.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Gout and uric acid nephropathy: some new aspects in diagnosis and treatment.

Authors:  W Löffler; H A Simmonds; W Gröbner
Journal:  Klin Wochenschr       Date:  1983-12-15
  8 in total
  7 in total

1.  [Differential indications for uricosuric drugs and allopurinol].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-03-01

Review 2.  Clinical pharmacokinetics of allopurinol.

Authors:  G A Murrell; W G Rapeport
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

3.  Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; M Suda; K Higashino
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

4.  Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.

Authors:  W Löffler; R Landthaler; J X de Vries; I Walter-Sack; A Ittensohn; A Voss; N Zöllner
Journal:  Clin Investig       Date:  1994-12

Review 5.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.